ESC Premium Access

Comparative adherence between DOAC and VKA in patients with atrial fibrillation: a 23-year retrospective observational study in Canada

Presentation

About the speaker

Miss Shahrzad Salmasi

University of British Columbia, Vancouver (Canada)
0 follower

160 more presentations in this session

The impact of abnormal conduction zone on outcomes after catheter ablation for atrial fibrillation

Speaker: Associate Professor T. Mine (Hyogo, JP)

Thumbnail

Thromboembolic risk of movable type left atrial appendage thrombi in patients with atrial fibrillation under widespread use of anticoagulants

Speaker: Doctor M. Sugitani (Nishinomiya, JP)

Thumbnail

Rate and rhythm control treatment in the elderly and very elderly patients with atrial fibrillation: an observational cohort study of 1,497 patients

Speaker: Mr T. Klamer (Amsterdam, NL)

Thumbnail

One year outcome and analysis of peri-device leak of left atrial appendage occlusion devices

Speaker: Doctor M. Mansour (Montreal, CA)

Thumbnail

Risk prediction of atrial fibrillation and its complications in the community using high-sensitivity cardiac Troponin I: Results from the BiomarCaRE Consortium

Speaker: Doctor C. Boerschel (Hamburg, DE)

Thumbnail

Access the full session

Atrial fibrillation e-posters

Speakers: Miss S. Salmasi, Associate Professor T. Mine, Doctor M. Sugitani, Mr T. Klamer, Doctor M. Mansour...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

Renal decline in patients with atrial fibrillation treated with rivaroxaban or warfarin: a population-based cohort study in the United Kingdom

27 August 2021

ESC Premium Access

Net clinical benefit of direct oral anticoagulants in very elderly and high bleeding risk patients with atrial fibrillation who are often excluded from oral anticoagulation therapy: a nationwide popul

27 August 2021

ESC Premium Access

2MACE score predicts cardiovascular adverse events in real-world atrial fibrillation patients under rivaroxaban therapy. Data from EMIR study

27 August 2021

This platform is supported by

logo Novo Nordisk